Rusfertide (hepcidin mimetic)

Current understanding

To be populated as evidence accumulates.

Evidence log

• 2026-09-29 — Rusfertide Approval Expands Options and Improves Burdens in Polycythemia Vera: NCCN added rusfertide as a Category 1 recommended option for both low- and high-risk polycythemia vera following FDA approval of Mimrylo, formalizing its place alongside phlebotomy, hydroxyurea, and interferons in PV treatment algorithms (guideline update). (novelty: 4)
• 2026-09-01 — FDA Approves Mimrylo (rusfertide) for Polycythemia Vera: 2026-08-28 — FDA approved rusfertide (Mimrylo) for treatment of erythrocytosis in adults with polycythemia vera, establishing the first hepcidin-mimetic agent as a therapeutic option beyond cytoreduction and phlebotomy (regulatory approval). (novelty: 4)
• 2026-08-31 — FDA Approves First-of-its-Kind Drug for Polycythemia Vera (Rusfertide/Mimrylo): FDA approved rusfertide (Mimrylo) as the first hepcidin-mimetic therapy for adults with polycythemia vera not adequately controlled by existing therapies — first-in-class approval relative to phlebotomy, hydroxyurea, interferons, and JAK inhibitors (regulatory announcement). (novelty: 4)

Open questions

Related